Join        Login             Stock Quote

10 Health-Care Stocks To Consider Buying Now

 September 28, 2009 09:43 AM

Much as we had noted during an early run-through of the holdings of several of our Ultimate Stock-Pickers last month, health care continues to be an area of focus for our top managers. Given that the sector is one of the few areas where our analysts are still finding value, with 19 out of the 49 stocks we currently have rated 5 stars coming from the health-care sector, it didn't come as too much of a surprise. As you may recall from our recent overview of Vanguard PRIMECAP's (VPMCX) holdings, health-care stocks have been under pressure for much of this year over concerns about the impact that a government-sponsored health-care plan could have on the industry's profitability. The question for investors, though, has been whether or not these near-term issues will derail the long-term positive impact that the aging of the baby boomers is expected to have on the industry. Judging from the recent purchases by our Ultimate Stock-Pickers, the answer appears to be no.

While it would be easy to focus on only the top 10 health-care holdings of our top managers, which currently include 5-star names like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK), we thought we'd look a little bit deeper into the most recent high-conviction purchases made by our Ultimate Stock-Pickers in the sector. Despite already being the largest health-care holding of our top managers coming into the most recent period, Johnson & Johnson continues to be purchased with conviction, with at least one manager making a new money purchase in the stock. Merck and Novartis (NVS) are two other top health-care holdings that continue to draw the attention of our Ultimate Stock-Pickers, albeit with slightly less conviction than other purchases in the sector. This leaves us then with seven names that aren't in the top 10 health-care holdings, with almost all of them trading at levels below our Consider Buying price.

 10 Health-Care Stocks to Consider Buying Now

Fair Value
Price ($)
Fair Value
Number of Fund Owners
Johnson & Johnson ( %20%20%20%20%20%20%20%20%20%20%20%20JNJ) LowWide60.700.7615
Covidien, Ltd. ( %20%20%20%20%20%20%20%20%20%20%20%20COV) MediumNarrow40.350.626
Becton, Dickinson and Co. ( BDX) LowNarrow68.680.747
Abbott Laboratories ( %20%20%20%20%20%20%20%20%20%20%20%20ABT) LowWide46.350.687
Merck & Co., Inc. (MRK) MediumWide30.930.674
Medtronic, Inc. ( %20%20%20%20%20%20%20%20%20%20%20%20MDT) LowWide36.740.779
Bristol-Myers Squibb Co. (BMY) MediumWide22.330.804
Novartis AG ( %20%20%20%20%20%20%20%20%20%20%20%20NVS) LowWide48.700.672
Genzyme Corporation (GENZ) MediumWide56.410.694
Zimmer Holdings, Inc. (ZMH) MediumWide52.460.673
Stock Price and Morningstar Rating data as of 09-24-09.

Each of these seven stocks stands out not only because it was a high-conviction buy during the most recent period, but because each had new money committed to it by at least one of our top managers. Abbott Laboratories (ABT) had the most activity, being purchased by four managers and having seven of them hold positions in the name at the end of the second quarter. Genzyme (GENZ) was also purchased by multiple managers during the period, although we did note that one manager completely eliminated his stake in the biotech firm. Bristol-Myers Squib (BMY), Medtronic (MDT), and  Zimmer (ZMH) all benefited from high-conviction new money purchases during the quarter, but all of these names still paled in comparison to the activity seen in both Becton, Dickinson (BDX) and Covidien (COV).

Covidien's a Company Warren Buffett Would Love
As you may recall, we sat down back in June with Alex Morozov, the associate director of stock analysis for the Morningstar health-care team, to talk about Becton, Dickinson after it turned up on our list of new money purchases during the first quarter of 2009. As it turned out Alex wasn't the only person who liked Becton, Dickinson, as Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) stepped up during the second quarter and made a big new money commitment to the name. While Alex continues to believe there's upside in Becton, Dickinson, we wanted to get his thoughts on Covidien, another medical device firm he covers, which had three significant purchases during the quarter, two of which were new money investments. Having just returned from Covidien's Investor Day, Alex had plenty of fresh insight to offer us.

Alex, can you please give us a quick overview of Covidien's business? Covidien was formerly the health-care unit of Tyco International (TYC). The company develops, manufactures, and distributes medical and imaging devices, pharmaceuticals, and other health-care products to medical professionals worldwide. Through its predecessors, Covidien has an operating history that spans 140 years and boasts a direct sales presence in more than 50 countries worldwide.

What's the basis for the company's narrow economic moat? Does it have the potential to expand its moat?

Covidien's moatiest businesses can be found in its medical devices segment, where it enjoys the advantages of brand recognition, technological innovation, and substantial scale. Of particular note is its high-end medical device/surgical instruments business, where it essentially shares the market with Johnson & Johnson's Ethicon business. The areas of the surgical instruments field where Covidien competes are relatively sticky--especially in sophisticated surgical tools, where surgeons require constant training and switching costs are high.

The company also has a presence in lower-end basic surgical products, like sutures and syringes, where its scale and tight cost control offset a lack of differentiation, allowing Covidien to maintain its returns on capital. Covidien's recent market share advancements in the surgical devices area came at the expense of both its smaller competitors and Ethicon. As the company commands a greater presence in the operating room, its position is becoming defensible, given the significant technological and administrative hurdles its competitors would have to overcome in order to replace Covidien.

With its legacy pharmaceutical business, Covidien boasts a leading position in the production of controlled substances. As the manufacturing process for these products is tightly regulated by both the FDA and the DEA, the company's long history of dealing with both agencies represents a sizable barrier to entry.

While the company still has its share of businesses that lack substantial competitive advantage (contrast agents in imaging, medical supplies), their presence as a percentage of revenue has been gradually dwindling. The firm has also been actively pruning what we consider to be no-moat businesses and product lines, such as retail (divested), specialty chemical (for sale), and sleep diagnostics (sold), further enhancing its returns on invested capital. While we feel that Covidien's moat might be widening as a result of the improvements in its operations overall, regulatory uncertainty regarding competitive bidding and the impact of health-care reform on future hospital spending have precluded us from assigning it a wider moat.

Covidien seems to have been investing heavily in research and development, an area where you think that the company's efforts are finally bearing fruit. Where do you see the company getting the most bang for its research buck these days?

Covidien's investment in medical devices is yielding a number of promising product launches and technological advancements. The company's R&D prowess that had wilted under Tyco is starting to flourish again, with Covidien re-establishing itself as a powerhouse in surgical tools. The particular focus has been on providing products for procedures where favorable secular trends--such as the expansion of minimally invasive surgical applications based on their economic attractiveness, the adoption of new technologies that simplify and improve the quality of procedures, and the rapidly growing market for metabolic surgery--should fuel strong growth in the future.

What makes you believe Covidien is a good value at the current stock price?

Covidien's earnings should receive a significant boost longer term from its sales momentum and margin expansion, driven by favorable product mix and operational and financial leverage. The firm should see some improvement on its P&L as it benefits from a shift to higher-margin devices, leverages its general and administrative expenses, and lowers its tax rate. The boost to earnings will not, however, come at the expense of R&D, while improvements in gross margin due to product mix are likely to be offset somewhat by unfavorable foreign exchange given the firm's largely domestic manufacturing base. There are also some near-term earnings head winds as segments outside of devices, particularly pharmaceutical and imaging, face challenges, but at this point Covidien's EPS forecast for 2010 is in line with our projections. The firm's ongoing commitment to invest in the areas where it enjoys competitive advantage (as well as its willingness to de-emphasize product lines that don't generate sufficient returns on capital) solidifies our take on Covidien's ability to strengthen its competitive position in the long run.

How's the financial health of the company?

Covidien sports a healthy balance sheet and has commenced paying both a dividend and buying back shares. Further, given its strong cash flow from operations, Covidien should be able to maintain its current cash position without dialing down its acquisition strategy. To reiterate this point, management stated during the Investor Day that it plans to maintain its cash balance at its current level, which means that more than $1.5 billion in annual free cash flow will be dispersed for acquisitions, dividend payments, share buybacks, and debt reduction. Our average projected debt/capital ratio over the next five years is approximately 20%.

While Covidien might not be as clear-cut a story as Becton, Dickinson, Alex continues to believe that the stock represents an appealing long-term investment opportunity. He feels that Covidien's strong product pipeline, management team dedicated to maximizing returns on investment, and favorable secular trends bode well for its future prospects. With several of our top managers making new money purchases in the name during the most recent period (and six of them now holding positions in the stock), we feel he might be on to something here.

Disclosure: Bradley Meeks does not own shares in any of the companies mentioned above.

About the Author

Ultimate Stock-Pickers layers Morningstar's own stock recommendations over a cross-section of great investors' stock picks to uncover enticing opportunities. For more, visit the Ultimate Stock-Pickers homepage and sign up for Ultimate Stock-Pickers e-mail alerts.



Comments Closed

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Morningstar
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.